XenTech Overview

  • Founded
  • 2006
  • Status
  • Private
  • Employees
  • 33
  • Latest Deal Type
  • Grant
  • Investors
  • 3

XenTech General Information


Provider of patient-derived tumor xenograft models designed to foster therapeutic development in oncology. The company's models focus on the pre-clinical evaluation of oncology therapeutics by offering translational platforms, enabling doctors to avail of relevant tumor models and addressing tomorrow's needs in preclinical oncology research.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 4, rue Pierre Fontaine
  • 91000 Évry
  • France
+33 01 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

XenTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 16-Mar-2009 00000 Completed Generating Revenue
2. Seed Round 31-Oct-2008 00000 00000 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2006 Completed Startup
To view XenTech’s complete valuation and funding history, request access »

XenTech Patents

XenTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150316556-A1 Ssea4 and st3gal2 as chemotherapeutic drug response biomarkers Abandoned 01-Apr-2014 000000000000
ES-2693035-T3 Ssea4 and st3gal2 as biomarkers of response to chemotherapeutic drugs Active 01-Apr-2014 000000000000
EP-2927328-A1 Ssea4 and st3gal2 as chemotherapeutic drug response biomarkers Granted 01-Apr-2014 000000000000 0
EP-2927328-B1 Ssea4 and st3gal2 as chemotherapeutic drug response biomarkers Active 01-Apr-2014 000000000000
CA-2835179-A1 Markers for cancer prognosis and therapy and methods of use Abandoned 06-May-2011 C12Q1/6886
To view XenTech’s complete patent history, request access »

XenTech Executive Team (10)

Name Title Board Seat Contact Info
Jean-Gabriel Judde Ph.D President & Chief Scientific Officer
Marie Caussou Chief Financial Officer & Manager, Human Resources
Pascal Leuraud Ph.D Chief Operating Officer & Co-Founder
Delphine Nicolle Ph.D Study Director
Marie Tavernier Study Director
You’re viewing 5 of 10 executive team members. Get the full list »

XenTech Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

XenTech Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
OSEO Innovation Venture Capital Minority 000 0000 000000 0
Aurinvest Venture Capital Minority 000 0000 000000 0
IncubAlliance Accelerator/Incubator Minority 000 0000 000000 0
To view XenTech’s complete investors history, request access »